Skip to content

The Importance Of October 11, 2012 For Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) For Cystic Fibrosis

October 11, 2012

       Today, October 11, 2012 is important for Vertex Pharmaceuticals and orphan drug Kalydeco for several reasons (Vertex Pharmaceuticals’ October 11, 2012 Press Release) : 

  1. Data from a Phase II study of VX-809 in combination with Kalydeco (Ivacaftor) in patients with F508del, the most common Cystic Fibrosis (CF) mutation, is to be presented at the North American Cystic Fibrosis (NACF) Conference in Orlando, Florida, at 11:40 AM.
  2. The presentation is important as Vertex Pharmaceuticals plans to start a “pivotal program in early 2013, which is expected to evaluate VX-809 in combination with Kalydeco in patients with CF who have 2 copies (homozygous) of the F508del mutation, pending discussions with regulatory agencies”
  3. Also, Vertex Pharmaceutical will host a webcast today, October 11, 2012 at 6:30 PM EDT to discuss these data & updates to the company’s CF research & development program.  

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: